Chondroitin: Modest but Real Cartilage Protection Over Time

← Back to articles

Chondroitin sulfate is a sulfated glycosaminoglycan that, alongside collagen and aggrecan, forms the structural scaffold of articular cartilage. Oral chondroitin has been controversial in the US but remains a first-line osteoarthritis treatment in European guidelines (ESCEO, EULAR) — a gap that is driven largely by product quality and study design, not by irreconcilable evidence.

The Structure-Modifying Question

Unlike NSAIDs, chondroitin has shown disease-modifying effects in several MRI and radiographic trials. The 2017 CONCEPT trial (Reginster et al., PMID 28939627) randomized 604 patients with symptomatic knee OA to pharmaceutical-grade chondroitin sulfate 800 mg/day, celecoxib 200 mg/day, or placebo over 6 months. Both active treatments outperformed placebo on pain and function, with chondroitin showing similar efficacy to celecoxib. Longer trials (about 2 years) have shown slowing of joint-space narrowing — a structural endpoint — with chondroitin that is not seen with NSAIDs.

Why Some Trials Fail

Much of the negative chondroitin literature, including parts of the GAIT trial, used low-purity or low-molecular-weight product that is functionally different from pharmaceutical-grade chondroitin sulfate. The US supplement market carries wide quality variation — some products contain 50% or less of labeled content. Europe registers a prescription-grade form (chondroitin sulfate sodium, 800 mg daily) that consistently outperforms supplement-grade material in head-to-head trials.

Combining with Glucosamine

The MOVES trial (Hochberg et al., 2016; PMID 25589511) randomized 606 patients with Kellgren-Lawrence grade 2–3 knee OA and moderate-to-severe pain to glucosamine hydrochloride 1,500 mg/day + chondroitin sulfate 1,200 mg/day or celecoxib 200 mg/day for 6 months. WOMAC pain reductions were essentially identical (about 50% in both arms; non-inferiority confirmed). The combination is more commonly used than either alone, though the incremental benefit of combining versus single-agent is modest.

Safety and Limitations

Chondroitin is well-tolerated, with rare GI upset. Onset is slow — most trials show meaningful improvement by 2–3 months, with maximal benefit at 6 months. It is not appropriate for acute flares. Patients with end-stage OA (bone-on-bone) are unlikely to respond meaningfully; the intervention is most useful in mild-to-moderate OA where cartilage remains.